• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Atwec Technologies Inc
Naturalshrimp Incorporated
Pineapple Financial Inc. Common Stock
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (NY:ATNM)

1.130 +0.070 (+6.60%)
Official Closing Price Updated: 8:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 174,394
Open 1.090
Bid (Size) 1.020 (2,000)
Ask (Size) 1.150 (2,000)
Prev. Close 1.060
Today's Range 1.050 - 1.150
52wk Range 0.7351 - 1.740
Shares Outstanding 21,331,314
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Is Actinium Pharmaceuticals Stock Rising Today? ↗
December 12, 2025
The Actinium-225 (Ac-225) antibody radioconjugate demonstrated strong anti-tumor activity across multiple breast cancer models. 
Via Stocktwits
Actinium Pharmaceuticals Advances Trop-2 Targeted Alpha Radiotherapy Into Phase 1/2 Trials in the U.S. and Australia
December 11, 2025
Via AB Newswire

Performance

52-Week Range 35.1% below 52-week high
1.130
0.7452W Low 1.7452W High
1 Week 1.7% below 1-week high
0.951W Low 1.151W High

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (ATNM) traded between $0.74 and $1.74 over the past 52 weeks and last traded at $1.13, 35.1% below its 52-week high. Over the past week it ranged between $0.95 and $1.15.

Past 12 Months
+6.6%
-5.0%
+28.0%
-21.5%
-17.5%
-22.6%
1W +$0.07
1M -$0.06
3M +$0.25
6M -$0.31
YTD -$0.24
1Y -$0.33

ATNM was -22.6% over the past year, -21.5% over six months, -17.5% year to date, +6.6% in the last week.

12 Months vs Market
ATNM
-22.6%
DIA
+12.4%
SPY
+14.9%
QQQ
+17.5%
IWM
+11.1%

Over the past 12 months ATNM returned -22.6% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 1.21× 3-mo avg
Today 174,394 3-mo avg 143.7K
1W
117.8K
1M
111.9K
3M
143.7K
6M
152.5K
YTD
145.3K
1Y
163.6K

ATNM most recently traded 174,394 shares against a 3-month average daily volume of 143.7K.

More News

Read More
Actinium Pharmaceuticals (NYSEAMERICAN: ATNM) Begins European Phase 1 Trial of Nectin-4 Targeted Alpha Therapy for Multiple Solid Tumors
December 10, 2025
Via AB Newswire
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances ATNM-400 Targeting STEAP-1 Across Prostate, Breast, and Lung Cancer
December 09, 2025
Via AB Newswire
ATNM-400 Targets B7-H3 and Is Being Studied in a Phase 1 Clinical Trial in South Africa
December 08, 2025
Via AB Newswire
Actinium Pharmaceuticals Advances ATNM-400 B7-H3 Candidate Into Phase 1 Clinical Trial in South Africa
December 08, 2025
Via AB Newswire
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
May 27, 2025
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
ATNM Deadline: Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
May 23, 2025
From Rosen Law Firm
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Ultra Clean, and SoundHound and Encourages Investors to Contact the Firm
May 21, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and SoundHound and Encourages Investors to Contact the Firm
May 14, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
May 14, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
May 13, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Faruqi & Faruqi Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 26, 2025 - ATNM
May 11, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
May 09, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit
May 08, 2025
From Kirby McInerney LLP
Via Business Wire
News headline image
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
April 29, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
April 29, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
April 28, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
April 26, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM
April 25, 2025
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
April 23, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
April 21, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
April 20, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
April 17, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
April 16, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire

Frequently Asked Questions

Is Actinium Pharmaceuticals, Inc. (Delaware) Common Stock publicly traded?
Yes, Actinium Pharmaceuticals, Inc. (Delaware) Common Stock is publicly traded.
What exchange does Actinium Pharmaceuticals, Inc. (Delaware) Common Stock trade on?
Actinium Pharmaceuticals, Inc. (Delaware) Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Actinium Pharmaceuticals, Inc. (Delaware) Common Stock?
The ticker symbol for Actinium Pharmaceuticals, Inc. (Delaware) Common Stock is ATNM on the New York Stock Exchange
What is the current price of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock?
The current price of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock is 1.130
When was Actinium Pharmaceuticals, Inc. (Delaware) Common Stock last traded?
The last trade of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock was at 10/16/26 08:00 PM ET
What is the market capitalization of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock?
The market capitalization of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock is 24.10M
How many shares of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock are outstanding?
Actinium Pharmaceuticals, Inc. (Delaware) Common Stock has 24M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap